Archive


Category: cancer

  • How to Reduce the Cancer-Causing Properties of Meat

    What are the preparation methods to reduce exposure to carcinogens in cooked meat? What are some ways we can decrease our exposure to the carcinogenic substances in meat that are formed during cooking? At 0:15 in my video Carcinogens in Meat, I show a whole list of hazard factors. The first factor is “meat type,” […]

  • 100 Million People in America Are Saddled With Health Care Debt 

    Elizabeth Woodruff drained her retirement account and took on three jobs after she and her husband were sued for nearly $10,000 by the New York hospital where his infected leg was amputated. Ariane Buck, a young father in Arizona who sells health insurance, couldn’t make an appointment with his doctor for a dangerous intestinal infection […]

  • 2nd NSCLC Drug Development Summit

    The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. The industry is uniting to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication, NSCLC. Summit highlights: Explore emerging approaches when targeting […]

  • Key takeaways from ASCO’s annual meeting

    Last weekend, health care professionals, patients, scientists and biopharmaceutical researchers gathered for the American Society of Clinical Oncology’s (ASCO) annual meeting. With over 200 sessions and 2,500 poster presentations on the latest advances in cancer therapy, the future of cancer diagnosis and treatment is promising.

  • 4 Steps for Operationalizing the FDA’s Call To Improve Health Outcomes for All Patients

    C.K. Wang, Chief Medical Officer of COTA, Inc. In April, FDA Commissioner Dr. Robert Califf laid out areas of challenge and opportunity when it comes to improving health outcomes, restoring public trust in science, and making the most of our ongoing investments in data analytics and clinical research. More specifically, Califf made clear that our current healthcare […]

  • GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers

    A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in […]

  • Philips’ Future Health Index 2022 Report: 4 Key Trends to Know

    What You Should Know: – Today, Philips announced the publication of its Future Health Index (FHI) 2022 report: ‘Healthcare hits reset: Priorities shift as healthcare leaders navigate a changed world’. FHI is the largest global survey of its kind, analyzing feedback from nearly 3,000 healthcare leaders across 15 countries on the impact of digital health technology in the adoption […]

  • Scaling-Up Inclusive Healthcare Initiatives in Low- and Middle-Income Countries

    Non-communicable diseases (NCDs) are on the rise in low- and middle-income countries (LMICs), increasing the financial and health burden affecting these vulnerable populations. To reverse this trend will require not only resources, but also new business models for LMICs that can overcome the barriers patients face to receiving care, such as unaffordable, unavailable, or inaccessible […]

  • BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche

    Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as a treatment for certain lung cancers. Recently reported preliminary data suggest the small molecule could have advantages over currently available drugs in the same class from rivals Pfizer and Roche.

  • Regeneron is paying $900M for full rights to cancer drug partnered with Sanofi

    Regeneron Pharmaceuticals has big plans for cancer immunotherapy Libtayo and it believes it can better execute on them if it has full control of the drug, currently partnered with Sanofi. Regeneron struck a deal to pay Sanofi $900 million, plus another $200 million in milestones, to secure full global rights to the asset.

  • Outdated Pain Models & The Rise of New Science on Chronic Pain

    Yoni Ashar, Ph.D., Clinical Advisor at Lin Health More than 50 million adults in the United States – more than 20% – suffer from chronic pain, and more than 19.6 million adults have pain that interferes with their lives more days than not. The estimated cost of chronic pain is $635 billion – more than […]

  • St. Peter’s Health to Deploy Innovaccer Health Cloud for Optimized Care Management

    What You Should Know:   St. Peter’s Health, a regional nonprofit healthcare system in Helena, Montana, is moving to the InnovaccerⓇ Health Cloud’s Data Activation Platform to support its mission of providing exceptional and compassionate care that treats the whole person and improves the health, wellness, and quality of life for the communities it serves. The […]

  • 4th RAS-Targeted Drug Development Summit

    For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring […]

  • Black Salve Is a Dangerous Scam

    Is black salve, a paste made from bloodroot, safe and effective for the treatment of skin cancer? “Despite warnings from the American Academy of Dermatology and being listed as a ‘fake cancer cure’ by the FDA, black salve is still promoted on the internet through anecdotes and unsubstantiated claims as a natural alternative remedy for […]

  • Cancer Mortality Among Black Individuals in the US

    Cancer is the 2nd leading cause of death in the US, just behind heart failure. Yet in recent years, we have seen that improved prevention, screening and treatment has helped to avert 3.5 million deaths in the US over the past 3 decades. Despite these gains, we do see that cancer death rates are highly […]

  • Buried Under Dirt or Under Debt: Can Patients Survive the Struggle of Getting Care?

    Srulik Dvorsky, TailorMed CEO and Founder New patients at a cancer center in Michigan receive a 79-page handbook when their treatments commence. The handbook includes needed advice on what to eat and the side effects of chemotherapy drugs. One double-sided page features information about how to navigate the financial aspects of cancer treatment, including who […]

  • Reproducibility, Trust, and the Digital Laboratory

    Kevin Vigilante MD, MPH EVP, Chief Medical Officer at Booz Allen Hamilton George Plopper, Sr. Lead Technologist at Booz Allen Hamilton Over the last decade, there has been an increasing recognition that results published in scientific journals often cannot be reproduced by other scientists. This has been called the “reproducibility crisis” and has been described […]

  • CAR T without the toxicity: Kelonia gets $50M for a new take on cell therapy

    Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient’s cells made possible by the targeted delivery of a genetic payload. The startup, newly out of stealth with $50M in funding, claims its approach would offer manufacturing and safety advantages over other cell therapy technologies.

  • Targeted Radiopharmaceuticals Summit US (TRP US)

    The inaugural Targeted Radiopharmaceuticals Summit US  will bring together a worldwide community of specialists to address long-standing challenges in radiopharmaceutical development at all stages, from bench to bedside. Join them in Boston this July as they reveal the most important strategies for maximizing the value of their medications, not just to make them more financially feasible but […]

  • Cerner Collaboration to Increase Access to Cancer Clinical Trials

    What You Should Know: – Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. – Together they will be using the research-activated network of health systems, real-world data (RWD) and multiomics technology, developed by Freenome, with the goal to help accelerate early cancer detection. Importance of Early Cancer Detection […]

  • Report: More than 500 medicines in development to treat disorders of the blood

    Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet medical need in the United States. To meet the demand for new treatments, companies in America’s biopharmaceutical industry have spent years working across the biomedical ecosystem […]

  • OncoHost Raises $35M for AI-Powered Precision Oncology Platform

    What You Should Know: – OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. Additional investors included leading Israeli financial firm Leumi Partners, Israel’s largest pension fund Menora Mivtachim, OurCrowd and other existing investors. – The funding will […]

  • An Apple a Day May Keep the Pharmacist Away

    Which would save more lives: eating an apple a day or taking statin drugs? Does an apple a day really keep the doctor away? That’s a public health message that’s been around since 1866, but is it true? You don’t know, until you put it to the test. As I discuss in my video Flashback […]

  • Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines

    What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines. – Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and […]

  • 3 Steps to Approach & Tackle Digital Transformation in Healthcare

    Michael Norring, President and CEO of GCSIT Artificial intelligence (AI) is predicted to save the US healthcare economy $150 billion by 2026. Replacing legacy systems and changing standard operating procedures, hospitals are moving to capitalize on technology and the ways it can change a historically hesitant to change sector. The big question is how fast […]

  • Oxidized Cholesterol and Alzheimer’s Disease

    Oxidized cholesterol can be a hundred times more toxic than regular cholesterol, raising additional concerns about foods such as ghee, canned tuna, processed meat, and parmesan cheese. Too much cholesterol in the blood “has long been considered to act as a primary risk factor for developing Alzheimer’s disease and, possibly, Parkinson’s disease.” Striking images on […]

  • Nkarta’s natural killers flash potential as next-gen cell therapies for cancer

    Two natural killer (NK)cell therapy candidates from Nkarta now have preliminary Phase 1 clinical data suggesting these therapies are helping patients in two types of blood cancers. Nkarta therapies based on engineered NK cells could offer both efficacy and safety advantages over the first generations of cell therapies, which are made from a patient’s own […]

  • TCR-based Therapeutics for Solid Tumors Summit

    Are you using TCRs to target solid tumors yet? With Immunocore having achieved commercialization for the first TCR therapy in both the US and EU and Adaptimmune hot on their tail, 2022 is fast becoming the year for TCRs. Join the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the […]

  • Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions

    What You Should Know: – Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven precision oncology solutions to deliver precision oncology care. – Through this research agreement, VUNO will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for […]

  • Using NLP Technology To Uncover Real-World Patient Insights

    It’s estimated that humans create a combined 2.5 quintillion bytes of data each day – and that around 90% of all data to ever exist was created in just the last few years. As difficult as it is to ignore the massive impact that connected technologies and social media have had on the way we experience our world, it’s somehow even […]

  • Transcarent Launches Oncology Care for Collaborative Cancer Care Experience

    What You Should Know: – Transcarent, a new, different, and better health and care experience company for employees of self-insured employers and their families launches Transcarent Oncology Care, a collaborative cancer care experience that connects employees and their families with high-quality cancer care from leading cancer institutes, top-rated oncology providers and researchers, and clinical trial […]

  • GlaxoSmithKline expands its cancer scope with $1.9B Sierra Oncology acquisition

    GlaxoSmithKline is further building out its cancer drug portfolio by acquiring Sierra Oncology, a biotech whose FDA-ready myelofibrosis drug has clinical data showing advantages over a blockbuster product marketed by Incyte. The deal comes as GSK prepares a spinoff of its consumer products as part of a broader strategy to hone its focus on specialty […]

  • Viagra-Type Drugs and Melanoma Skin Cancer

    What is the role of erectile dysfunction drugs like Cialis and Levitra in the promotion and progression of prostate cancer and melanoma? Of the half-dozen Viagra-type drugs on the market now, Viagra itself may have “the greatest efficacy but also the highest rate of overall adverse events,” or side effects. It’s still a pretty safe […]

  • PathAI and GlaxoSmithKline Partner to Accelerate Research and Drug Development

    What You Should Know: – PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs in oncology and non-alcoholic steatohepatitis (NASH). – As part of the partnership, GSK will leverage both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better […]

  • Potential of Implementing Polygenic Risk Scores in Healthcare Systems

    Dr. George Busby, co-founder and Chief Scientific Officer at Allelica The promise of personalized medicine is a world in which interventions, screening, and therapeutics are targeted to those most likely to get the disease. Polygenic risk scores will help society reach this ambition by accurately assessing the contribution that one’s DNA makes to disease risk.  […]

  • Blueberries Can Improve Artery Function

    What is the optimum dose of wild blueberries to eat at a meal? A single serving of blueberries can help mediate the arterial dysfunction induced by smoking a cigarette. Researchers investigated the effect of a single serving of frozen blueberries on young smokers. As you can see at 0:19 in my video Benefits of Blueberries […]

  • Digital Health Disconnect Creates Unnecessary Roadblock to Patient Engagement

    Aaron Kaufman, EVP at Carenet Health By all accounts, the last two years have accelerated consumer adoption of digital tools for managing nearly every aspect of our lives. Ordering takeout? Odds are good you used a digital payment method, alongside the 93% of consumers who say they’ve used tools like Venmo and Zelle over the last year. Visiting your primary care […]

  • COTA Promotes Miruna Sasu to President and CEO

    Miruna Sasu, Ph.D., MBA, President & CEO at COTA, Inc. What You Should Know: – COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer.  – Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has […]

  • Why Mainstream Precision Medicine Hinges on Healthcare HPC Storage

    Adam Marko, Director of Life Science Solutions at Panasas The healthcare industry is experiencing a data deluge, and it shows no sign of slowing down. In 2020, estimates reported that healthcare data comprised a staggering 30% of the world’s total data volume; projections for 2025 bump that number up to 36%, a growth rate outpacing […]

  • Tempus Launches Pathology-Driven AI Platform

    What You Should Know: – Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. – With access to over 50 petabytes of de-identified […]

  • Canopy Launches Out of Stealth with $13M for Intelligent Care Platform for Oncology

    What You Should Know:  – Today,  Canopy announced it is launching out of stealth with $13 million in funding to work with leading oncology practices all over the country to help deliver high-quality care to cancer patients when they aren’t in the doctor’s office. – Canopy works with leading oncology practices nationwide to drive the […]

  • Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration

    Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage […]

  • House Rx Secures $30M to Optimize the Specialty Pharmacy Experience for Patients and Their Care Teams

    What You Should Know: – Today House Rx, a health technology platform that empowers oncology and rheumatology physician practices with medically integrated dispensing, announced they’ve secured $30 million in financing. – Founded by two former Flatiron Health executives, Ogi Kavazovic and Tesh Khullar the company has partnered with four medical practices and 30 prescribers since March 2021. House Rx, a […]

  • Nektar drug key to muti-billion dollar BMS deal fails pivotal test in melanoma

    Bristol Myers Squibb bet more than $1.8 billion that Nektar Therapeutics’ drug could be combined with the pharma giant’s Opdivo to expand the reach of that drug to more patients. The drug combination has failed its first Phase 3 in advanced melanoma; separate studies in kidney and bladder cancers are ongoing.

  • MediView XR Secures $9.9M for Augmented Reality Surgical Navigation Platform

    What You Should Know: – MediView XR, Inc., raises $9.9M in SAFE financing syndicated by Inside View Investments, LLC, a private investment firm.  MediView has raised approximately $14.4MM in total funding to date. – Investment will support key technology development, commercialization and regulatory submissions. MediView XR Inc., a Cleveland-based medtech company that leverages augmented reality, remote connectivity […]

  • To Engage and Activate Patients, CRM Alone Isn’t Enough

    Michael Linnert, Founder and CEO of Actium Health We talk about patient engagement a lot in healthcare today. But the reality is, we often don’t just want a patient to engage with a piece of content or information; we want them to take action. The traditional CRM and marketing automation are great tools for the […]

  • Why The End of the Public Health Emergency is Everyone’s Problem

    Heather Korbulic, Senior Policy and Strategy Lead, GetInsured The COVID-19 pandemic led to sweeping healthcare policy changes that enable vulnerable Americans to receive affordable health coverage and access essential safety net benefits. The steep incline in unemployment and fears that millions of people would lose their health coverage drove the declaration of the national public health emergency (PHE) on January 31, 2020. Under the […]

  • Black Female Co-founders CancerIQ Raises $14M to Improve Cancer Early Detection and Prevention

    CancerIQ Co-Founders Feyi Olopade Ayodele & Olufunmilayo (Funmi) Olopade, MD What You Should Know: – CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round. – The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures […]

  • Massachusetts General Hospital to Co-Develop VR Digital Therapeutic for Stem Cell Patients

    What You Should Know: – Massachusetts General Hospital (“MGH”) announced a research agreement with Rocket VR Health, an emerging digital therapeutics company developing clinically validated virtual reality therapies that enhance the quality of life of cancer patients, their families and their caregivers. – The research will study the effects of daily Virtual Reality Therapy’s effect […]

  • XRHealth Secures $10M to Expand Virtual Reality Treatment in the Metaverse

    What You Should Know: – XRHealth, the gateway to the healthcare metaverse,  announced today that they raised $10M in funding to expand virtual healthcare treatment in the Metaverse. The funding was backed by HTC, Bridges Israel impact investment fund, AARP, and crowdfunding on StartEngine.com and existing investors. – XRHealth’s platform is FDA and CE registered and provides an immersive […]

  • Crisis in the U.S. Healthcare Workforce: Why It’s Time to introduce AI

    Andrew Pucher, CEO of Dascena, Inc. One of the many acute challenges during the pandemic has been the departure of approximately 18% of the U.S. healthcare workforce,4 resulting in staffing shortages in hospitals. This has impacted the well-being of the remaining healthcare practitioners 5 as well as their patients – many of whom are deferring […]

  • Benchling Acquires Overwatch Research to Accelerate Breakthroughs for Biopharma Companies

    What You Should Know: – Today, R&D Cloud pioneer Benchling announced it has acquired Overwatch Research to accelerate in vivo research. – The acquisition will create the industry’s first comprehensive, cloud-native in vivo solution – a critical component of drug discovery and development – drastically accelerating the time it takes biopharma companies to bring products […]

  • 4 things to know about biopharmaceutical efforts to fight cancer

    A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which examined the long-term effects of CAR-T cell therapy, characterized one of the first patients treated as part of clinical trials in 2010 as “cured,” a term rarely used in oncology. […]

  • Mayo Clinic Tests Shark Cartilage Supplements for Cancer

    Shark cartilage supplements carry risks, but so do many cancer treatments. The question is, do they work? When it comes to marketing unproven cancer treatments, the “Internet has become the Wild West, so to speak. Fraudsters are really able to…get out there in ways they hadn’t before to take advantage of people.” “Cancer Patients Find […]

  • Why The Future of Healthcare Interfaces is Fluid

    Sajjad Kamal, Healthtech Partner at Global Ventures Nazmus Saquib, HCI & Interfaces Expert Tools we use to do our daily work have rapidly evolved following deep human-computer interaction (HCI) research.  However, when it comes to healthcare, the HCI research has not found its way to healthcare practice. Most healthcare professionals still rely on memory, experience, […]

  • Medtronic, AWS to Provide Underserved Communities with AI-Assisted Colon Cancer Screening

    Genius Intelligent Endoscopy Module What You Should Know: – Medtronic and AWS, today announced a partnership to provide underserved communities with artificial intelligence (AI)-assisted colonoscopy technology through AWS’s $40M Health Equity Assistance Program for colon cancer screening. – Amazon Web Services will support the effort to provide Medtronic GI Genius™ intelligent endoscopy modules to facilities […]

  • Connecting the Dots – Building Data Bridges for a Better Healthcare Future

    Jen Goldsmith, President Tendo Systems Healthcare data is increasing at an exponential rate. Approximately one-third of the world’s data volume is being generated by the healthcare industry. By 2025, the compound annual growth rate of healthcare data will reach 36% – that’s 6% faster than manufacturing, 10% faster than financial services, and 11% faster than […]

  • Helping Clinical Trial Sites Improve Study Recruitment and Retention

    Tzvia Bader, CEO and co-founder, TrialJectory The clinical trial industry is, once again, at an uncertain crossroads. And while it might be assumed that the outsized impact of the COVID-19 pandemic has resulted in the inability to recruit patients for trials, it is instead, a challenge generated, over time, by the industry itself. Thankfully, there […]

  • Medicaid Coverage of Family Planning Benefits: Findings from a 2021 State Survey

    This report presents survey findings from 41 states and DC about coverage policies for fee-for-service Medicaid in place as of July 1, 2021, for the following categories of family planning benefits: prescription contraceptives, over-the-counter methods, STI & HIV services, well woman care, breast & cervical cancer services, and managed care services

  • Do Cell Phones Affect Cognitive Function?

    The World Health Organization concluded that cell phone radiation may cause brain tumors, but what about effects on cognitive function? “At present, we do not know precisely the degree to which the risk of cancer and other adverse health effects are increased by the exposure to the RF [radiofrequency] fields from cell phones, smart meters, […]

  • Roivant Sciences launches Hemavant to chase BMS in anemia from blood disease

    An Eisai drug that produced disappointing data in a myelodysplastic syndrome study is getting another shot under a newly launched Roivant Sciences subsidiary, Hemavant. Roivant executives say the small molecule could be a safer, more effective alternative to MDS therapies marketed by Bristol Myers Squibb.

  • C2i Genomics, Twist Bioscience Partner to Develop Whole-Genome Cancer Reference Materials

    What You Should Know: – Today, Twist Bioscience and cancer genomics startup C2i Genomics announced a partnership to develop whole-genome cancer reference materials. – This resource will provide diagnostic labs around the globe with the ability to better validate and monitor the quality of their whole-genome cancer screening and minimal residual disease (MRD) products for […]

  • Johnson & Johnson faces push to force global ban on talc baby powder sales

    Move to hold shareholder vote follows withdrawal of product in US and Canada and lawsuits alleging link to cancer cases The healthcare company Johnson & Johnson is facing an attempt to force a shareholder vote to halt its sales of talc-based baby powder across the world, including the UK, amid concerns over alleged links to […]

  • Racial Disparities in Cancer Outcomes, Screening, and Treatment

    This brief provides an overview of recent data on cancer incidence and mortality, risk factors, screening, treatment, and outcomes by race and ethnicity. Racial disparities in cancer incidence and outcomes are well-documented, with research showing that they are driven by a combination of structural, economic, and socioenvironmental inequities that are rooted in racism and discrimination, […]

  • Are Provoked Urine Challenge Tests for Heavy Metals a Scam?

    Is testing for body burden of heavy metals like mercury with “urine mobilization tests,” “challenge tests,” and “provoked urine tests” just a scam? Environmental risk factors, meaning non-genetic risk factors, may play a significant role in autism. Identical twins who share the same DNA may not share the condition more than half the time. A […]

  • Jasper Health Raises $25M for Cancer Care Navigation and Experience Platform

    What You Should Know: – Jasper Health, an NYC-based cancer care coordination and experience platform raise $25M in Series A funding led by General Catalyst. – The round, which was joined by new and existing investors Human Capital, W Health Ventures, Redesign Health, and 7wireVentures, brings Jasper’s total funding to approximately $31 million. End-to-End Oncology Solution 1.8 million […]

  • New Cancer Care Navigator Thyme Care Starts Out with $22M Series A & Big Name Backing

    By JESSICA DaMASSA, WTF HEALTH Thyme Care is a cancer navigation platform that is looking to use technology to make the kind of high-touch care coordination usually only found at Centers of Excellence available to oncology practices across the country. The navigation we’re talking about is typically quarterbacked by experienced oncology nurse navigators, and is […]

  • Do Any Benefits of Alcohol Outweigh the Risks?

    What would happen if you effectively randomized people at birth to drink more or less alcohol their whole lives? Would they get more or less heart disease? Once you remove the “systematic error” of misclassifying former drinkers as if they were lifelong abstainers from studies on alcohol and mortality, moderate alcohol consumption, like a glass […]

  • Is It Better to Drink a Little Alcohol Than None at All?

    Even if alcohol causes cancer and there is no “French paradox,” what about the famous J-shaped curve, where excessive drinking is bad, but light drinkers appear to actually have lower mortality than abstainers? “Why do we not see the corporate interests of the alcohol industry as clearly as we see those of the tobacco industry?” […]

  • Biliary tract cancer drug granted orphan drug designation in US

    The US regulator has granted biliary tract cancer therapy Silmitasertib orphan drug designation. There are currently no treatments for this rare cancer, and the US food and Drug Administration (FDA) hopes that pharmaceutical firm Senhwa’s drug will meet the significant need for new biliary tract cancer options. First-line standard of care is currently a chemotherapy […]

  • Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer

    What You Should Know: – Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer. – This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021. Generate Real-World Evidence in Breast Cancer […]

  • Sugemalimab plus chemo boosts lung cancer survival, trial reveals

    Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. PD-1 inhibitors work against the protein, […]

  • The Best Source of Resveratrol

    Is there any benefit to resveratrol? If so, should we get it from wine, grapes, peanuts, or supplements? “Alcohol is a neurotoxin which can cause brain damage…[and] can cause cancer,” so perhaps the “consumption of alcohol…cannot be considered a healthy lifestyle choice” since it’s an addictive carcinogen. Cancer is only killer number two, though. Killer […]

  • Clinical trial begins of lung cancer immunotherapeutic

    Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. The novel immunotherapeutic, VTP-600, is not a preventative vaccine — it’s intended for patients who have recently been diagnosed with non-small cell lung cancer. The […]

  • Scotland backs AstraZeneca drug as first-line treatment for NSCLC

    Scotland has approved AstraZeneca’s Tagrisso (osimertinib) as a monotherapy for the for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Lung cancer is linked to a quarter of all cancer deaths in the country, with almost half of lung […]

  • Can Alcohol Cause Cancer?

    If even light drinking can cause cancer, why don’t doctors warn their patients about it? As I discuss in my video Can Alcohol Cause Cancer?, we’ve known about “the possible association of the consumption of alcohol with excessive mortality from cancer” for more than a hundred years. Though there is “accumulating evidence that alcohol drinking […]

  • Long-Excluded Uterine Cancer Patients Are Step Closer to 9/11 Benefits

    Tammy Kaminski can still recall the taste of benzene, a carcinogenic byproduct of burning jet fuel. For nine months after the 9/11 attacks, she volunteered for eight hours every Saturday at St. Paul’s Chapel, just around the corner from ground zero in New York City. She breathed in cancer-causing toxic substances, like fuel fumes and […]

  • Apple Peels Put to the Test for Chronic Joint Pain

    Are the health benefits associated with apple consumption simply due to other healthy behaviors among apple-eaters? Regular apple intake is associated with all sorts of benefits, such as living longer and, more specifically, a lower risk of dying from cancer. At 0:17 in my video Apple Peels Put to the Test for Chronic Joint Pain, […]

  • Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer

    The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.

  • Putting patient perspectives at the heart of kidney cancer research

    Kidney cancer is the 14th most common cancer, with approximately 400,000 new cases worldwide every year. Renal cell carcinoma (RCC) is by far the most prevalent type of cancer originating from the kidney, making up nine out of ten kidney cancer diagnoses. As chief medical officer, head of global medical affairs, patient safety and patient […]

  • Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy

    That is the title of my recent paper in Advances in Therapy along with co-authors Christian Jackisch, Federico Manevy, Suzanne Frank, and Nicki Roberts. This is a case study of the fixed-dose combination therapy of pertuzumab and trastuzumab as a subcutaneous injection compared to previous treatments which were administered via infusion. The abstract is below. […]

  • BMS joins off the shelf cell therapy chase with alliance on Immatics cancer drug

    Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and […]

  • How to Balance the Risks and Benefits of Mammograms

    Fact boxes can quantify benefits and harms in a clear and accessible format.  When it comes to cancer screening, doctors “have too often ignored” the fact that women may place different weights on various pros and cons, so they have just “focused on persuading rather than educating” and letting people make up their own mind. […]

  • Doctors Tested for Basic Understanding of Mammogram Math

    If doctors don’t understand health statistics, how can they possibly properly counsel patients?  “In these mammography wars, rational thinking can be easily lost.” Mammograms are big business, bringing in about seven billion dollars a year, but it would be a bit too “cynical to believe” that the pushback from mammogram critics “stems only from self-interest […]

  • KFF’s Kaiser Health News Wins NABJ Award for Excellence in Radio Journalism for a Story About Teaching Children to Cope with the Constant Threat of Gun Violence in Their Communities

    The National Association of Black Journalists has recognized KFF’s Kaiser Health News and two of its editorial partners with a 2021 “Salute to Excellence” award for a radio story about how children are taught to cope and survive in communities beset by gun violence. The story, Teaching Kids To Hide From Gunfire: Safety Drills At…More

  • Breast Cancer Can Grow and Spread for Decades Before “Early” Detection

    “Early” detection is actually really late. Without mammograms, breast cancer may not be caught for an average of 22.8 years. With mammograms, though, breast cancer may only grow and spread for…21.4 years. Critics of breast cancer screening claim that, on a population scale, mammograms have never been shown to actually prolong women’s lives on average. […]

  • Learn More Than 97% of Doctors About Lead-Time Bias

    After reading this, you’ll know more than an estimated 97 percent of doctors about a critical concept called lead-time bias.  While running for president of the United States, former New York mayor Rudy Giuliani ran a campaign ad contrasting his 82 percent chance of surviving prostate cancer in the United States with the 44 percent […]

  • FDA turns down BeyondSpring chemo complication drug, asks for another trial

    BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.

  • Does Cell Phone Radiation Affect Fertility?

    What is the effect of cell phone radiation on sperm motility and DNA damage? “Are men talking their reproductive health away?” There have been “unexplained declines in semen quality reported in several countries.” Might cell phones be playing a role? “Radio-frequency electromagnetic radiation (RF-EMR) from these devices could potentially affect sperm development and function.” The […]

  • Did the Oncology Care Model produce cost savings?

    The answer is ‘yes’, but the magnitude of these savings are relatively small and more than offset by additional OCM program costs. Keating et al. (2021) writes: In this exploratory difference-in-differences study of Medicare fee-for-service beneficiaries with cancer undergoing chemotherapy (483 310 beneficiaries with 987 332 episodes treated at 201 OCM participating practices and 557 354 beneficiaries with […]

  • Overtreatment of Ductal Carcinoma In Situ

    Nine out of ten women don’t realize that some breast cancers would never have caused any problems or even become known in one’s lifetime. This is an issue ductal carcinoma in situ has brought to the forefront. The whole point of cancer screening is to “detect life-threatening disease at an earlier, more curable stage. Effective […]

  • Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

    Shots: Gaeta to receive $0.2M up front and is eligible to receive ~$7.5M in clinical and regulatory milestones based on product and indication The agreement will expand Oncorus’ clinical development of ONCR-177 for the treatment of cancer patients in combination with pembrolizumab and other immunotherapies, and also helps to bolster the commercialization strategy of the […]

  • Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment

    Thomas Bock, M.D., Chief Executive Officer of Notable What You Should Know: – Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes. – Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify […]

  • Millions of Years of Healthy Life Lost Due to Cannabis

    Every year, cannabis is estimated to result in two million years of healthy life lost due to disability. How much is that compared with alcohol and tobacco? “The popular notion seems to be that marijuana is a harmless pleasure,” but what are the potential adverse effects of marijuana use? That’s not an easy question to […]

  • Biotech startup Marengo unveils $80M and a new way to get T cells to fight cancer

    Apple Tree Partners’ latest cancer biotech company, Marengo Therapeutics, is using antibodies to selectively activate T cells to fight cancer. Led by former Merck KGaA executive Zhen Su, the startup is launching with $80 million in financing, which will support a drug pipeline that includes a lead program expected to reach the clinic in 2022.

  • Biologics manufacturing drives Evotec’s $435M U.S. stock market debut

    Evotec is an old player in the life sciences, but in offering new shares on the Nasdaq, the Germany-based company plans to bolster its new biologics manufacturing capabilities in the U.S and Europe. In other stock market debuts, IO Biotech’s IPO raised $100 million as it prepares a pivotal test of its lead cancer immunotherapy.

  • Those Who Claim the Greatest Benefit From Mammograms May Ironically Suffer the Most Harm

    The mammogram paradox is that women who are harmed the most, are the ones who claim the greatest benefit. While false-positive results, pain during the procedure, and radiation exposure may be among the most frequent harms associated with mammogram screening, overdiagnosis “is now recognized as the most serious downside of population breast screening.” Overdiagnosis is […]

  • How Much Cancer Do Mammograms Cause?

    What is the risk-benefit ratio of the cancers picked up by mammograms and the cancers caused by mammograms? Over the last few decades, our radiation exposure has nearly doubled, due almost exclusively to medical sources, such as CT scans. While we’ve known that higher dose radiation from CT scans and angiograms, for example, can cause […]

  • Using bispecific antibodies to advance cancer immunotherapy

    Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Bispecific antibodies (bsAbs) are designed to recognise two different epitopes and, compared to current monovalent antibody therapeutics, bsAbs have enhanced binding, specificity, and efficacy, making them exciting candidates for more targeted cancer treatments. In 2019, there were […]

  • Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

    Shots: The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients with cancer The collaboration will bolster the clinical development of combination immunotherapy for multiple solid tumors & the companies plan to submit an IND application to the NMPA imminently Innovent […]

  • Do Mammograms Have to Be Painful?

    Excessive breast compression during mammography may not improve image quality and can cause unnecessary pain.  False-positive results have been described as “the most frequent harm” associated with mammogram screening, but it actually may be the pain. “There is a wide variation both in the reported frequency of pain and in degree of pain felt by […]

  • Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs

    Cancer drug developer Xilio Therapeutics and Ventyx Biosciences, a company with drug candidates in cancer and autoimmune diseases, are the latest life science companies to go public. They’ll use proceeds from their respective IPOs to continue clinical development of drugs being positioned as competitors to drugs from big pharmaceutical companies.

  • Most Women May Experience at Least One False-Positive Mammogram

    Odds are most women will get at least one false-positive mammogram, but, thankfully, most women who are called back for further testing of a suspicious mammogram finding do not end up having cancer after all.  In response to the Swiss Medical Board’s recommendation against women of any age getting routine mammograms, critics suggested that instead […]

  • How Is It Possible That Mammograms Don’t Actually Save Lives?

    For every life saved by mammography, as many as two to ten women are overdiagnosed and unnecessarily turned into breast cancer patients with all of the attendant harms of chemo, radiation, or surgery, without the benefits. What was the impact of the 2009 shift in recommendations by the U.S. Preventive Services Task Force (USPSTF) to […]

  • Untapped Opportunities for Oncology Medical Affairs Striving for better access and more equitable cancer care in communities nationwide

    Pharmaceutical companies’ traditional medical education model relies on prominent researchers and publishers in the oncology space, otherwise known as Key Opinion Leaders (KOLs), to spread information about the newest therapies. There remain, however, significant untapped opportunities for oncology medical affairs to penetrate communities and reach more practitioners nationwide. Medical Science Liaisons that currently focus their […]

  • Next Generation CAR-TCR Summit

    The cell therapy field is showing no signs of slowing down, with huge investment and excitement around next generation products and their clinical validation in solid tumour indications. Formerly CAR-TCR Europe, the new and improved Next Generation CAR-TCR Therapies Summit is now the only industry-dedicated forum focused on the 2.0, next generation innovations in cell therapies. This year, we’ll be specifically focusing […]

  • Why Doctors Should Not Encourage Breast Self-Exams

    Various health organizations offer clashing mammogram recommendations that range from annual mammograms starting at age 40 to eliminating routine mammograms altogether. Who can you trust? Clashing mammogram recommendations ranging from annual mammograms starting at age 40 to eliminating routine mammograms altogether are offered by various health organizations. It’s hard to know who to trust given […]

  • Exo Therapeutics adds $78M as cancer, inflammation drugs march toward clinic

    Biotech startup Exo Therapeutics aims to overcome the challenges of drugging proteins by targeting exosites, locations that modulate enzyme activity. The company has four small molecule drug candidates for cancer and inflammation, and the company plans to use the $78 million in new financing to advance them toward human testing.

  • Why Are Mammogram Guidelines Conflicting? 

    When women are fully informed about the risks and benefits of mammograms, 70 percent may choose not to get screened. You may be in that 30 percent who opts to get a mammogram and absolutely have the right to decide for yourself.  “For nearly a century, public health organizations, professional associations, patient advocacy groups, academics, and clinicians largely viewed cancer screening as a simple, […]

  • England’s cancer therapy backlog ‘could take more than a decade to shift’

    A new report has suggested it could take until 2033 to clear the backlog of cancer treatment in England caused by the pandemic. The analysis by the Institute for Public Policy Research (IPPR) and Carnall Farrar (CF) consultancy suggests that timeline will be the result if hospitals can operate at a level 5% above what […]

  • 90% of Women Appear Misinformed About Mammograms 

    Most women are just being told what to do, rather than being given the facts needed to make a fully informed decision.   “Selling cancer screening can be easy,” begins an editorial in the Journal of the National Cancer Institute. “Induce fear by exaggerating risk. Offer hope by exaggerating the benefit of screening. And don’t mention harms [caused by the screening]. It is especially easy […]

  • Covid-Overwhelmed Hospitals Postpone Cancer Care and Other Treatment

    It’s a bad time to get sick in Oregon. That’s the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated. Charlie Callagan looked perfectly healthy sitting outside recently on his deck in the smoky summer air in the small Rogue Valley town of Merlin, in southern Oregon. […]

  • Takeda therapy gets speedy FDA nod for lung cancers with rare genetic signature

    Takeda Pharmaceutical drug mobocertinib was approved by the FDA to treat non-small cell lung cancer in patients whose tumors carry a rare genetic signature. With the approval, Takeda can offer an oral alternative to a recently approved Johnson & Johnson drug that targets the same mutation but is given as an infusion.

  • Lead Contamination in Calcium Supplements 

    Do calcium citrate and calcium carbonate have as much lead as calcium supplements derived from dolomite and animal bone?  You may remember I’ve explored the role calcium supplements may play in reducing lead exposure during pregnancy and breastfeeding, but that assumes the supplements themselves are not contaminated. Supplements with lead?  It all started with an extraordinary case report published in 1977, entitled “Lead-Contaminated Health Food.” As I discuss in my video Lead in Calcium […]

  • The Effects of Nutritional Yeast for Cancer 

    How can the beta glucan fiber in brewer’s, baker’s, and nutritional yeast improve wound healing and, potentially, anti-cancer immunity?  My video Benefits of Nutritional Yeast for Cancer opens with an image of an article titled “The Treatment of Inoperable Cancer.” It noted that “200 years ago it was observed that a certain number of malignant growths disappeared after an attack of erysipelas [a type of […]

  • Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment

    What You Should Know: – Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease. […]

  • Startup Modulus embraces AI to design better NK cell therapies for cancer

    Modulus Therapeutics recently emerged from stealth with technology from various disciplines and seed funding that the startup is using to develop better cell therapies. Natural killer cells directed against breast cancer is Modulus’s initial focus, but the startup says its approach can apply to multiple types of immune cells and multiple types of cancer.

  • Targeting COVID-19 and cancer with immunotherapy advancements

    Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections. Monoclonal antibodies (mABs) are highly specific therapies associated with […]

  • How pharma can help the post-COVID recovery of European cancer care

    The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered. The publication, which has been supported by Accord Healthcare, also provides a series of […]

  • Recognizing National Immunization Awareness Month

    Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean drinking water in leading to some of the most impactful public health advances in history, including the eradication of smallpox globally and measles, […]

  • MedStar Health, MercyOne, Moffitt Cancer Center, Others Double Down on Digital Transformation

    What You Should Know: – AVIA, the nation’s leading healthcare innovation network, today announced that the following six new health system Members joined the AVIA Network to accelerate their digital strategies and advance digital capabilities: Lee Health, LifeBridge Health, MedStar Health, MercyOne,   Moffitt Cancer Center, Multicare. Additionally, AVIA had a record of 100% plus renewal rate from existing Members. – Executive leaders from health systems are prioritizing digital and understand the critical role it plays to […]

  • Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care

    What You Should Know: – Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common […]

  • A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D

    Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.

  • Jasper Health Integrates BioIntelliSense’s RPM and COVID-19 Screening Solution for Members

    What You Should Know:  – Today, BioIntelliSense announced it has formed a strategic collaboration with Jasper Health, an emerging leader of digital engagement for people diagnosed with cancer. – As part of the strategic collaboration, Jasper Health will integrate the BioIntelliSense FDA-cleared BioSticker and medical grade BioButton® wearable devices as part of its remote member […]

  • Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

    What You Should Know:  – Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop […]

  • UPMC launches cancer drug discovery company

    Called Novasenta, the company is focused on the tumor microenvironment and will leverage its machine-learning platform to pinpoint targets for drug development. It aims to launch its first clinical trial by the end of 2023.

  • Soy Phytoestrogens for Menopausal Symptoms

    Does soy food consumption explain why Japanese women appear to be so protected from hot flash symptoms? When women hit menopause and their ovaries shut down, the estrogen level in their body drops 95 percent. This is good news for the endometrium, the lining of the uterus. Otherwise, the constant estrogen signaling could eventually result in endometrial cancer. In fact, […]

  • AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

    AstraZeneca’s Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca’s 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. Alexion focuses on finding medications for […]

  • Pfizer makes big move in blood cancers with $2.3B Trillium acquisition

    Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the Trillium Therapeutics acquisition have safety and efficacy advantages that could make them the best in this emerging drug class.

  • FDA decision for GSK drug opens door to treatment of more cancer patients

    GlaxoSmithKline drug Jemperli is now FDA approved for treating solid tumors throughout the body as long as they have a particular genetic signature. Expanding the drug’s approval means the drug can treat more patients who have more types of cancer, and it also gives GSK a way to grow revenue in its thin oncology portfolio.

  • Sesen Bio says rejected bladder cancer drug may need new clinical trial

    For much of this summer, Sesen Bio said all of the FDA’s communications pointed toward regulatory approval for the biotech’s bladder cancer drug. Though Sesen characterized the regulator’s rejection of the fusion protein as surprising, CEO Tom Cannell also revealed an earlier sign that another clinical trial may be necessary.

  • Noncoding RNA Therapies

    I was mentioning the number of unusual therapeutic modes that are being explored these days, and one of those is (broadly) RNA-based approaches. The ones that directly feed into coding for proteins get a lot of attention (the mRNA vaccines, for example), and everything that’s currently approved is some sort of antisense or siRNA species. […]

  • The Dangers of Talcum Powder

    What role does diet and baby powder play in the development of fibroids and ovarian cancer?  If you randomly select a group of women and ultrasound their uterus, most of them have fibroid tumors by age 50—and by most, I mean more than 80 percent of black women and nearly 70 percent of white women. As you can see at 0:23 in my video Talcum […]

  • Breast cancer drug approved for NHS after maker agrees discount

    Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer. The decision has been described as “fantastic […]

  • Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer

    Shots: Appia Bio to receive $875M as an up front, equity investment, and milestone along with royalties. Kite will be responsible for the development, manufacturing, and commercialization of the product identified through the collaboration The collaboration will utilize Kite’s chimeric Ag receptors and Appia Bio’s allogeneic cell technology platform to develop off-the-shelf cell therapies Appia […]

  • A New Pathway To Kill Resistant Breast Cancer

    As all the recent news about protein folding should make clear, there are a lot of ways for any given protein sequence to come together into a three-dimensional structure. For that phrase “a lot”, substitute “a larger number than the human mind can possibly comprehend”, and you’ll be about right. Biologically, many proteins already display […]

  • Dr. Greger’s Daily Dozen Healthiest of Healthy Foods 

    In my book How Not to Die, I center my recommendations around a Daily Dozen checklist of everything I try to fit into my daily routine.  In my book How Not to Die, I suggest we try to center our diets around whole plant foods. Some plants are healthier than others, though. Apparently, you can live for extended periods eating practically nothing but white potatoes, for example, […]

  • Is medical cannabis really a magic bullet?

    Research increasingly suggests that extracts from the plant are effective in treating pain, anxiety, epilepsy and more, but experts still preach caution around recreational use In 2017, Mikael Sodergren, a liver and pancreatic cancer surgeon at Imperial College healthcare NHS trust, was finding himself becoming increasingly interested in the potential role of medical cannabis in […]

  • Radiation and Immunotherapy Together

    Cancer immunotherapy has been a huge topic in recent years, and deservedly so. But there are some types of tumors that respond much better than others, which means that there are also some that hardly respond at all. A great deal of effort is going into trying to find ways to make these immunologically “cold” […]

  • Wugen unveils $172M to take natural killer cell therapies to solid tumors

    Wugen, a biotech developing “off-the-shelf” natural killer and CAR T cell therapies, has raised $172 million in Series B financing. The company’s lead program has already reached human testing and the new capital will be used to continue that research and advance other pipeline programs to the clinic.

  • A Fifty-Year-Old Cancer Drug Doesn’t Do What You Think

    5-fluorouracil (5-FU) has been around a long time now (over fifty years), and it’s a standard oncology drug (particularly in colorectal treatment regimes). But try going around and asking people how it works. If you’re talking to a clinician and want to seem up on the lingo, just say “What’s 5-FU’s MOA?” (mechanism of action). […]

  • Elekta to work with academics on AI-directed radiotherapy

    Radiotherapy specialist Elekta has joined forces with two academic groups in the Netherlands to explore the use of artificial intelligence (AI) to deliver more effective personalised therapy to patients.  The Swedish company will collaborate with scientists at the Netherlands Cancer Institute and University of Amsterdam (UvA) on a project that aims to use AI to […]

  • What HCPs think about health equity in cancer care

    After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in healthcare. CREATION.co’s Mary Kangley explores what HCPs think about health equity in cancer care. The topic rose to significance in the American Society of Clinical Oncology (ASCO) whereby they updated […]

  • Oil Pulling for Cancer? 

    What evidence exists to suggest oil pulling can effectively treat serious diseases, such as paralysis, meningitis, cancer, and AIDS?  I’ve produced videos on how coconut oil is safe to put on your hair or put on your skin, but you certainly don’t want to eat it. In fact, you may not even want to be in the same kitchen when coconut oil is being heated. I don’t know where people got the idea […]

  • Health Innovators: Eliot Forster, F-Star

    In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the lives of patients with cancer.     About the author Dr Paul Tunnah is chief content officer and UK managing director for Healthware Group, a next-generation integrated consulting group that […]

  • What mRNA is Good For, And What It Maybe Isn’t

    The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. Moderna and BioNTech, of course, have been thinking this way for quite some time. But Sanofi now says that they’ll be investing large amounts into the technology, and this previously hadn’t been […]

  • Novobiocin Returns? But Not as an Antibiotic.

    Here’s some interesting work from Dana-Farber (earlier BioRxiv version here) that may turn into a rare example of repurposing an old drug, if it works out. The team was studying an enzyme called DNA polymerase theta (also known by its corresponding gene name, POLQ), which is one of the lesser-known members of that functional family. […]

  • Goal Attainment Scaling

    What outcomes should be used to measure if a medicine is a “good” medicine? Improved survival? Improved ability to function? Few side effects? Ability to get back to work? Living to attend your daughter’s wedding? All of the above? Oftentimes, health economists measure value of a treatment for the average person. Preferences for efficacy, safety, […]

  • ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more

    The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.